DOM-CANDESARTAN TABLET

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

CANDESARTAN CILEXETIL

Beszerezhető a:

DOMINION PHARMACAL

ATC-kód:

C09CA06

INN (nemzetközi neve):

CANDESARTAN

Adagolás:

32MG

Gyógyszerészeti forma:

TABLET

Összetétel:

CANDESARTAN CILEXETIL 32MG

Az alkalmazás módja:

ORAL

db csomag:

30/100

Recept típusa:

Prescription

Terápiás terület:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Termék összefoglaló:

Active ingredient group (AIG) number: 0135220004; AHFS:

Engedélyezési státusz:

CANCELLED PRE MARKET

Engedély dátuma:

2019-02-07

Termékjellemzők

_Dom-CANDESARTAN Product Monograph_
_Page 1 of 38_
PRODUCT MONOGRAPH
PR
DOM-CANDESARTAN
Candesartan cilexetil tablets
4 mg, 8 mg, 16 mg and 32 mg
ANGIOTENSIN II AT
1 RECEPTOR BLOCKER
DOMINION PHARMACAL
6111 Av. Royalmount, Suite 100
Montréal, Québec
H4P 2T4
DATE OF REVISION
:
October 19, 2016
Submission Control No: 198053
_Dom-CANDESARTAN Product Monograph_
_Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
..................................................................................................
14
DOSAGE AND ADMINISTRATION
.............................................................................
16
OVERDOSAGE
................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 19
STORAGE AND STABILITY
.........................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 22
PART II: SCIENTIFIC INFORMATION
.............................................................................
23
PHARMACEUTICAL INFORMATION
.........................................................................
23
CLINICAL TRIALS
.........................................................................................................